Stocktwits

BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300

Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ ...